Preventive Efficacy of a Tenofovir Alafenamide Fumarate Nanofluidic Implant in SHIV‐Challenged Nonhuman Primates (Adv. Therap. 3/2021)

In article number 2000163, Alessandro Grattoni and colleagues perform the first ever HIV preventive efficacy study using a subcutaneous drug delivery implant. The implant uses a nanofluidic membrane to sustainably deliver tenofovir alafenamide fumarate (TAF), a HIV antiretroviral, without pumps or actuation. Long‐term sustained TAF release, controlled through physical and electrostatic confinement in the nanochannels of the membrane, obviates daily oral dosing to provide protection from HIV infection in nonhuman primates.